Trial · NCT01753323
Participant flow21
How many started, completed or left each group, period by period.
1 to 20 of 21
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Part 1 - Cohort 1: P. Vivax: KAF156 400mg QD | 11 | |
| Overall Study | STARTED | Part 1 - Cohort 2: P. Falciparum: KAF156 400mg QD | 10 | |
| Overall Study | STARTED | Part 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose | 22 | |
| Overall Study | Pharmacodynamic (PD) Set | Part 1 - Cohort 1: P. Vivax: KAF156 400mg QD | 10 | |
| Overall Study | Pharmacodynamic (PD) Set | Part 1 - Cohort 2: P. Falciparum: KAF156 400mg QD | 10 | |
| Overall Study | Pharmacodynamic (PD) Set | Part 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose | 21 | |
| Overall Study | Pharmacokinetic(PK) Set | Part 1 - Cohort 1: P. Vivax: KAF156 400mg QD | 10 | |
| Overall Study | Pharmacokinetic(PK) Set | Part 1 - Cohort 2: P. Falciparum: KAF156 400mg QD | 10 | |
| Overall Study | Pharmacokinetic(PK) Set | Part 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose | 21 | |
| Overall Study | Safety Set | Part 1 - Cohort 1: P. Vivax: KAF156 400mg QD | 11 | |
| Overall Study | Safety Set | Part 1 - Cohort 2: P. Falciparum: KAF156 400mg QD | 10 | |
| Overall Study | Safety Set | Part 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose | 22 | |
| Overall Study | Intent-to-treat Analysis Set | Part 1 - Cohort 1: P. Vivax: KAF156 400mg QD | 11 | |
| Overall Study | Intent-to-treat Analysis Set | Part 1 - Cohort 2: P. Falciparum: KAF156 400mg QD | 10 | |
| Overall Study | Intent-to-treat Analysis Set | Part 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose | 22 | |
| Overall Study | COMPLETED | Part 1 - Cohort 1: P. Vivax: KAF156 400mg QD | 10 | |
| Overall Study | COMPLETED | Part 1 - Cohort 2: P. Falciparum: KAF156 400mg QD | 10 | |
| Overall Study | COMPLETED | Part 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose | 13 | |
| Overall Study | NOT COMPLETED | Part 1 - Cohort 1: P. Vivax: KAF156 400mg QD | 1 | |
| Overall Study | NOT COMPLETED | Part 1 - Cohort 2: P. Falciparum: KAF156 400mg QD | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01753323/flow